June 01, 2026 a 06:00 pm
INCY: Fundamental Ratio Analysis - Incyte Corporation
Incyte Corporation is a reputable player in the biopharmaceutical field with a focus on developing innovative therapies. The company's robust pipeline and existing therapies like JAKAFI and ICLUSIG show significant potential. With ongoing collaborations with several key players in the industry, Incyte is well-positioned for sustained growth. However, uncertainties in clinical trial outcomes and market competition may present challenges.
Fundamental Rating
Incyte Corporation displays strong fundamentals, reflected in its overall score of 4. Each category contributes positively, with particular strengths in DCF and ROE.
| Category | Score | Visual Representation |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 4 | |
| Price to Earnings | 2 | |
| Price to Book | 2 |
Historical Rating
Historical analysis indicates stable performance with consistent scores across the categories over the recent periods.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | 4 | 5 | 5 | 5 | 4 | 2 | 2 |
| Previous | N/A | 5 | 5 | 5 | 4 | 2 | 2 |
Analyst Price Targets
Analyst estimates suggest a positive outlook with a consensus price target slightly above the median. Key levels indicate significant upside potential.
| High | Low | Median | Consensus |
|---|---|---|---|
| $135 | $90 | $107 | $108.55 |
Analyst Sentiment
The majority of analysts maintain a positive stance with a "Buy" consensus, underscoring confidence in Incyte's market strategy and growth trajectory.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 23 | |
| Hold | 19 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
In summary, Incyte Corporation emerges as a resilient entity within the biotechnology sector, driven by promising therapeutics and dynamic partnerships. The company's fiscal health, coupled with optimistic analyst outlooks, strengthens its investment narrative. Still, ongoing clinical trials pose inherent risks. Investors should monitor these developments closely to navigate potential market fluctuations effectively.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years